Protective Effect of Palonosetron against Cisplatin-Induced Cytotoxicity via Decreased Phosphorylation of p38
Biological and Pharmaceutical Bulletin · 2025
DOI: 10.1248/bpb.b25-00193 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biological and Pharmaceutical Bulletin, 2025. Verfasst von Masayoshi Kondo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hospital Pharmacy, School of Pharmaceutical Sciences, The University of Osaka, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan. Hauptthemen laut MEDLINE: Cisplatin, Palonosetron, p38 Mitogen-Activated Protein Kinases, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
The dose-limiting nephrotoxicity of cisplatin (CDDP) is attributed to its accumulation in renal epithelial cells, mediated by uptake via human organic cation transporter 2 (hOCT2) and efflux via human multidrug and toxin extrusion 1 (hMATE1), followed by apoptosis induction via p38 phosphorylation. Recently, we demonstrated that the incidence of CDDP-induced nephrotoxicity was significantly lower in patients receiving palonosetron, a 5-hydroxytryptamine 3 receptor antagonist (5-HT3RA), than in those receiving other 5-HT3RAs (ondansetron, ramosetron, and granisetron). However, the underlying mechanism through which palonosetron induces a renoprotective effect remains unclear. In this study, we investigated the effects of 5-HT3RAs (palonosetron, ondansetron, ramosetron, and granisetron) on hOCT2- and hMATE1-mediated transport of CDDP, as well as on CDDP-induced cytotoxicity. In the CDDP uptake study, none of these 5-HT3RAs inhibited hOCT2-mediated transport of CDDP at concentrations of 0.1 and 1 μM, except for 10 μM (above clinical concentration). However, ondansetron and ramosetron, unlike palonosetron or granisetron, potently inhibited the hMATE1-mediated transport of CDDP at concentrations of 0.1 and 1 μM. In human embryonic kidney (HEK293) and porcine kidney (LLC-PK1) epithelial cells, all the tested 5-HT3RAs (1 μM), except granisetron, reduced CDDP-induced cytotoxicity. Moreover, co-incubation with palonosetron, ondansetron, and ramosetron suppressed CDDP-induced p38 phosphorylation in HEK293 cells. Thus, these findings suggest that concomitant treatment with palonosetron reduces CDDP-induced cytotoxicity by inhibiting p38 phosphorylation, but does not inhibit the hOCT2-mediated transport of CDDP. The present findings provide novel insights into the reduction of CDDP-induced cytotoxicity through concomitant palonosetron treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hospital Pharmacy, School of Pharmaceutical Sciences, The University of Osaka, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan.
- Department of Pharmacy, The University of Osaka Hospital, 2-15 Yamadaoka, Suita, Osaka 565-0871, Japan.
Zitieren
APA
Kondo, M., Yamane, F., Kawashima, K., Ikemura, K., & Okuda, M. (2025). Protective Effect of Palonosetron against Cisplatin-Induced Cytotoxicity via Decreased Phosphorylation of p38. Biological and Pharmaceutical Bulletin. https://doi.org/10.1248/bpb.b25-00193
Vancouver
Kondo M, Yamane F, Kawashima K, Ikemura K, Okuda M. Protective Effect of Palonosetron against Cisplatin-Induced Cytotoxicity via Decreased Phosphorylation of p38. Biological and Pharmaceutical Bulletin. 2025. doi:10.1248/bpb.b25-00193
BibTeX
@article{Kondo2025,
author = {Kondo, Masayoshi and Yamane, Fumihiro and Kawashima, Kotaro and Ikemura, Kenji and Okuda, Masahiro},
title = {Protective Effect of Palonosetron against Cisplatin-Induced Cytotoxicity via Decreased Phosphorylation of p38},
journal = {Biological and Pharmaceutical Bulletin},
year = {2025},
doi = {10.1248/bpb.b25-00193}
}
EUVIMED